NIH × Graft vs Host Disease × Clear all
NCT00001873 2018-09-26

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT00025662 2016-10-28

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
23 enrolled 11 charts
NCT00079391 2015-10-26

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 12 charts
NCT00462657 2013-08-26

Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

National Cancer Institute (NCI)

Phase NA Unknown
200 enrolled
NCT00004255 2013-07-10

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

National Cancer Institute (NCI)

Phase 2/3 Completed
NCT00740467 2010-01-28

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
NCT00001748 2008-03-04

HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
35 enrolled